

A. Numbers of African American (AA) and European American (EA) patients with each cancer type included in this analysis. BRCA, breast cancer; CESC, cervical cancer; OV, ovarian cancer; UCEC, uterine corpus endometrial cancer; and UCS, uterine carcinosarcoma. B,C. Ingenuity Pathway Analyses of transcriptional network changes in the cisplatin- and MEFC2-associated expression pathways in AA vs. EA tumors. Relative changes in gene expression are depicted from lower (green) to higher (red) expression in AA samples. Database-predicted activator relationships are orange; predicted inhibitor relationships are blue, and red indicates unpredicted effects.